Morningstar

Morningstar, Inc.

Equity Bottom-Up

ICU Medical's first-quarter results continue the firm's pattern of volatile top-line performance, this time falling somewhat short of our and consensus expectations. As we update our model, we'll likely leave our $248 fair value estimate in place, as accounting for the cash flows received since our last update largely offsets a modestly lower earnings outlook. On a positive note, the firm continues to defend its bottom line, with adjusted earnings consistent with our model resulting in…

United States

ICU Medical, Inc. develops, manufactures, and sells disposable medical connection systems for use in intravenous (IV) therapy applications.  The Company's products are designed to prevent accidental disconnection of IV lines and to protect healthcare workers and their patients from the spread of infectious disease such as Hepatitis B and Human Immunodeficiency Virus (HIV).

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00